Glaukos Corporation filings document the regulatory record for an ophthalmic pharmaceutical and medical technology company with common stock listed on the New York Stock Exchange under GKOS. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary net sales information, supplemental business summaries, and Regulation FD investor presentations.
The company’s proxy materials provide governance and executive-compensation disclosures, including equity-award and pay-versus-performance information. These filings also identify Glaukos as a Delaware corporation and frame disclosure around its glaucoma, corneal-disorder, and retinal-disease therapies, commercial products, risk disclosures, and public-company reporting obligations.
GLAUKOS Corp director Leana Wen reported receiving equity compensation on May 28, 2026. She was granted 1,878 restricted stock units under the company’s Director Compensation Policy; these units vest in full one year after the grant and will be settled in an equal number of common shares.
She also received a stock option for 2,987 shares of common stock at an exercise price of $53.57 per share, vesting in full one year after the grant and expiring on May 28, 2036. After these awards, Wen directly holds 21,617 shares of common stock, which the filing notes include previously granted restricted stock units that are unvested or deferred.
GLAUKOS Corp director Aimee S. Weisner received new equity compensation awards. On May 28, 2026, she was granted 1,878 restricted stock units under the company’s Director Compensation Policy. These units vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of common shares.
She was also granted 2,987 stock options with an exercise price of $53.57 per share, vesting in full one year after the grant and expiring on May 28, 2036. Following these awards, she holds 20,684 common shares directly, in addition to indirect holdings of 2,000 shares through the Weisner Saeman Family Irrevocable Trust and 29,505 shares through the Saeman-Weisner Family Trust. These are compensation-related grants rather than open-market purchases or sales.
GLAUKOS Corp director Denice Torres reported equity awards as part of standard board compensation. She received 1,878 restricted stock units that will vest in full on the one-year anniversary of the grant date and convert into the same number of common shares. She was also granted stock options for 2,987 shares of common stock with an exercise price of $53.57 per share, vesting in full after one year and expiring in 2036. Following these grants, she directly holds 24,212 shares of common stock, which include 4,609 restricted stock units that have not yet vested or been delivered.
GLAUKOS Corp director Mark J. Foley received equity compensation consisting of new restricted stock units and stock options. He was granted 1,878 restricted stock units under the company’s Director Compensation Policy, which will vest in full on the one-year anniversary of the grant date and then convert into the same number of common shares.
Foley was also granted stock options covering 2,987 shares of common stock with an exercise price of $53.57 per share, also vesting in full one year after the grant date and expiring in 2036. After these awards, he directly holds 60,267 shares of common stock, including 5,154 restricted stock units that have not yet vested or been delivered, highlighting this filing as a routine, compensation-related acquisition rather than an open-market purchase or sale.
GLAUKOS Corp director David F. Hoffmeister reported equity compensation awards. He received 1,878 restricted stock units under the company’s Director Compensation Policy, which vest in full on the one-year anniversary of the May 28 grant and are payable in the same number of common shares.
He also received stock options for 2,987 shares of common stock at an exercise price of $53.57 per share, vesting in full after one year and expiring on May 28, 2036. Following these awards, he holds 49,549 shares directly, including 4,739 unvested or deferred restricted stock units, and 38,176 shares indirectly through Sentinel Point Partners, Inc.
GLAUKOS Corp director Gilbert H. Kliman received new equity awards as part of the company’s director compensation program. He was granted 1,878 shares of common stock in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and will be settled in an equal number of shares.
He also received a stock option for 2,987 shares of common stock with an exercise price of $53.57 per share, vesting in full one year after the grant and expiring on May 28, 2036. After these awards, Kliman directly holds 37,406 shares of common stock. Footnote disclosure states this total includes 4,609 restricted stock units that are either unvested or vested but with delivery deferred.
GLAUKOS Corp director Marc Stapley reported compensation-related equity grants. He received 1,878 restricted stock units under the company’s Director Compensation Policy, which vest in full on the one-year anniversary of the May 28, 2026 grant and will be settled in the same number of common shares. He was also granted stock options covering 2,987 shares of common stock at an exercise price of $53.57 per share, vesting in full one year after the grant and expiring on May 28, 2036. Following these awards, Stapley directly holds 39,327 shares of common stock, which include 4,713 restricted stock units that are unvested or deferred for later delivery.
GLAUKOS Corp director David F. Hoffmeister exercised stock options to acquire 15,000 shares of Common Stock at $24.69 per share. The exercised options were granted on June 2, 2016 and were fully vested by the first anniversary of the grant date, and now show zero remaining. After the transaction, he holds 47,671 shares of Common Stock directly, which include 2,861 restricted stock units that are unvested or deferred, and 38,176 shares indirectly through Sentinel Point Partners, Inc.
GLAUKOS Corp director Gilbert H. Kliman exercised stock options and sold shares in the company. He exercised options for 5,000 shares of common stock at $24.69 per share, then sold 5,000 shares in the open market at an average price of $140.76 per share.
After these transactions, he directly owns 35,528 shares of common stock, which includes 2,731 restricted stock units that have not yet vested or been delivered, as well as vested units with deferred delivery. The option exercised was granted on June 2, 2016 and fully vested one year later, with no remaining balance after this exercise.
Janus Henderson Group plc reports beneficial ownership of 5,348,395 shares of Glaukos Corp common stock. The filing states the shares are held by multiple Janus Henderson asset managers on behalf of managed portfolios and are reported with shared voting and dispositive power of 5,348,395 shares, representing 9.2% of the class. The filing disclaims rights to dividend or sale proceeds by the asset managers and identifies related exhibits for subsidiary classification.